Printer Friendly
The Free Library
14,538,373 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Kyowa Hakko Kogyo to Expand Its Fuji Plant and Accelerate R&D for Antibody Drugs.


Tokyo Tokyo (tō`kēō), city (1990 pop. 8,163,573), capital of Japan and of Tokyo prefecture, E central Honshu, at the head of Tokyo Bay. , Japan, June June: see month.  23, 2006 - (JCN JCN Japan Corporate News
JCN Journal of Cognitive Neuroscience
JCN Journal of Cardiovascular Nursing
JCN Journal of Christian Nursing
JCN Job Control Number
JCN Journal of Child Neurology
JCN joint communications network (US DoD) 
) - Kyowa Hakko Kogyo announced on June 21 that it has decided to construct new facilities at its Fuji Plant.

Specifically, the company will invest 3-4 billion yen (US$26.0-34.7 mil An Internet address domain name for a military agency. See Internet address.

(networking) mil - The top-level domain for entities affiliated with US armed forces.
) to build GMP-compliant facilities for animal cell culture/purification.

Construction will begin in early 2007, and commercial operations will start in the first quarter of 2009. With this move, the company aims to reinforce the research and develop system of antibody drugs for clinical trial use.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Jun 23, 2006
Words:94
Previous Article:Riken Discovers New Mechanism for Controlling Allergic Reactions.
Next Article:Kobayashi Pharmaceutical to Market New Nutritional Supplement Product via Mail-Order.



Related Articles
Kyowa Hakko Kogyo, Mitsubishi Pharma Obtain Additional Approval for Recombinant Alteplase Agents.
Kyowa Hakko Kogyo to Release Plant-derived Glucosamine for Commercial Use in September.
Kyowa Hakko Chemical to Increase Production Capacity of 2-Ethyl Hexanoic Acid.
Kyowa Hakko Kogyo Licenses Anti-tumor Drug Candidate Mitotic Kinesin Eg5 Inhibitor to Eli Lilly.
Kyowa Hakko Kogyo Begins Operations at New Plant in China.
Kyowa Hakko Kogyo Completes Overseas Phase III Clinical Trials for KW-6002, Anti-Parkinson's Disease Agent.
Meiji Dairies, Kyowa Hakko Kogyo Receive Approval for MRI Digestive Tract Contrast Medium BOTHDEL.
Alcon Japan, Kyowa Hakko Kogyo to Join Hands in Sales and Promotion of Olopatadine Hydrochloride Ophthalmic Solution.
Kyowa Hakko Develops World's First Fermentation-based Commercial Production Method for L-Tyrosine.
Kyowa Hakko Licenses Anticancer Agent KW-2401 to Keryx Biopharmaceuticals.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles